Medication Monitor

Generic Name (Trade Name—Company)
June 13, 2011


(Potiga—Valeant, GlaxoSmithKline)
Indicated for adjunct treatment of partial-onset seizures


Adjunctive treatment of partial-onset seizures in adults 

Ezogabine is the first neuronal potassium channel opener approved for the management of patients with epilepsy. Activation of potassium currents mediated by the KCNQ family of ion channels results in stabilization of the resting membrane potential and a reduction in brain excitability. Patients randomized to total daily maintenance ezogabine dosages of 600 mg/d, 900 mg/d, or 1,200 mg/d had significant reductions in seizure frequency over a 28-day period, compared with placebo. According to a press release by Valeant and GlaxoSmithKline, the drug will not be available until later this year because FDA has recommended that the drug be classified as a controlled substance due to its euphoric effects. Final classification is still under review by the Drug Enforcement Administration.